Generation of human tumor-specific CTLs in HLA-A2.1–transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors

By Gritzapis Angelos   Sotiriadou Nectaria   Papamichail Michael   Baxevanis Constantin  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 11, 2004-11 ,pp. : 1027-1040

Springer Publishing Company

Access to resources Recommend Favorite

Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice

By Machlenkin Arthur   Azriel-Rosenfeld Ronit   Volovitz Ilan   Vadai Ezra   Lev Avital   Paz Adrian   Goldberger Ofir   Reiter Yoram   Tzehoval Esther   Benhar Itai   Eisenbach Lea  

Cancer Immunology, Immunotherapy, Vol. 56, Iss. 2, 2007-02 ,pp. : 217-226

Springer Publishing Company

Access to resources Recommend Favorite

Transgenic Mice as a Source of Fully Human Antibodies for the Treatment of Cancer

By Davis C.G.   Gallo M.L.   Corvalan J.R.F.  

Cancer and Metastasis Reviews, Vol. 18, Iss. 4, 1999-12 ,pp. : 421-425

Springer Publishing Company

Access to resources Recommend Favorite

A new tyrosinase epitope recognized in the HLA-B*4002 context by CTL from melanoma patients

By Godet Yann  

Cancer Immunology, Immunotherapy, Vol. 58, Iss. 2, 2009-02 ,pp. : 271-280

Springer Publishing Company

Access to resources Recommend Favorite

Human leukocyte antigen distribution analysis in North Italian brain Glioma patients: an association with HLA-DRB1*14

By Guerini Franca   Agliardi Cristina   Zanzottera Milena   Delbue Serena   Pagani Elisabetta   Tinelli Carmine   Boldorini Renzo   Car Pier   Veggiani Claudia   Ferrante Pasquale  

Journal of Neuro-Oncology, Vol. 77, Iss. 2, 2006-04 ,pp. : 213-217

Springer Publishing Company

Access to resources Recommend Favorite